Amaia Lujambio

List of Publications by Year
in descending order

87 papers	8,047 citations	159585 30 h-index	85541 71 g-index
91 all docs	91 docs citations	91 times ranked	13210 citing authors

#	Article	IF	Citations
1	The microcosmos of cancer. Nature, 2012, 482, 347-355.	27.8	993
2	A microRNA DNA methylation signature for human cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13556-13561.	7.1	990
3	Genetic Unmasking of an Epigenetically Silenced microRNA in Human Cancer Cells. Cancer Research, 2007, 67, 1424-1429.	0.9	883
4	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 2021, 592, 450-456.	27.8	649
5	Non-Cell-Autonomous Tumor Suppression by p53. Cell, 2013, 153, 449-460.	28.9	603
6	Î²-Catenin Activation Promotes Immune Escape and Resistance to Antiâ€“PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1124-1141.	9.4	498
7	A combinatorial strategy for treating KRAS-mutant lung cancer. Nature, 2016, 534, 647-651.	27.8	337
8	The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Research, 2009, 19, 438-451.	5.5	218
9	Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut, 2017, 66, 1286-1296.	12.1	198
10	Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nature Medicine, 2022, 28, 1599-1611.	30.7	185
11	CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene, 2010, 29, 6390-6401.	5.9	183
12	CpG Island Hypermethylation of Tumor Suppressor microRNAs in Human Cancer. Cell Cycle, 2007, 6, 1454-1458.	2.6	170
13	CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes and Development, 2014, 28, 1800-1814.	5.9	167
14	How epigenetics can explain human metastasis: A new role for microRNAs. Cell Cycle, 2009, 8, 377-382.	2.6	143
15	Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-Î² Pathway. Cell Reports, 2017, 18, 2480-2493.	6.4	135
16	An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell, 2016, 30, 485-498.	16.8	130
17	A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer. Cancer Cell, 2015, 27, 223-239.	16.8	128
18	IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Gastroenterology, 2016, 151, 1192-1205.	1.3	103

#	Article	IF	Citations
19	CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle, 2007, 6, 1455-9.	2.6	98
20	Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. Cell, 2018, 174, 1200-1215.e20.	28.9	96
21	Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell, 2020, 37, 584-598.e11.	16.8	96
22	To clear, or not to clear (senescent cells)? That is the question. BioEssays, 2016, 38, S56-64.	2.5	88
23	Molecular Analysis of a Multistep Lung Cancer Model Induced by Chronic Inflammation Reveals Epigenetic Regulation of p16, Activation of the DNA Damage Response Pathway. Neoplasia, 2007, 9, 840-IN12.	5.3	86
24	Epigenetic disruption of cadherinâ€11 in human cancer metastasis. Journal of Pathology, 2012, 228, 230-240.	4.5	60
25	Splicing regulator SLU7 is essential for maintaining liver homeostasis. Journal of Clinical Investigation, 2014, 124, 2909-2920.	8.2	55
26	Epigenetic Compensation Promotes Liver Regeneration. Developmental Cell, 2019, 50, 43-56.e6.	7.0	49
27	Cooperation Between Distinct Cancer Driver Genes Underlies Intertumor Heterogeneity in Hepatocellular Carcinoma. Gastroenterology, 2020, 159, 2203-2220.e14.	1.3	47
28	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
29	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut, 2023, 72, 736-748.	12.1	42
30	Novel patient-derived preclinical models of liver cancer. Journal of Hepatology, 2020, 72, 239-249.	3.7	41
31	Epigenetic Activation of SOX11 in Lymphoid Neoplasms by Histone Modifications. PLoS ONE, 2011, 6, e21382.	2.5	38
32	Histone Acetyltransferase Activity of MOF Is Required for <i>MLL-AF9</i> Leukemogenesis. Cancer Research, 2017, 77, 1753-1762.	0.9	38
33	BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nature Medicine, 2021, 27, 851-861.	30.7	38
34	USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer. Journal of Biological Chemistry, 2017, 292, 4164-4175.	3.4	37
35	Nuclear factor erythroid 2â€"related factor 2 and Î²â€Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications. Hepatology, 2021, 74, 741-759.	7.3	32
36	TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell, 2022, 29, 298-314.e9.	11.1	23

#	Article	IF	Citations
37	Liver metastases inhibit immunotherapy efficacy. Nature Medicine, 2021, 27, 25-27.	30.7	20
38	DNA sensing in senescence. Nature Cell Biology, 2017, 19, 1008-1009.	10.3	18
39	Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity. Blood, 2019, 134, 727-727.	1.4	18
40	Therapeutic editing of hepatocyte genome in vivo. Journal of Hepatology, 2017, 67, 818-828.	3.7	17
41	Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma. Cancers, 2020, 12, 3397.	3.7	17
42	Bivalent histone modifications in stem cells poise miRNA loci for CpG island hypermethylation in human cancer. Epigenetics, 2011, 6, 1344-1353.	2.7	16
43	Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. Molecular Cancer Therapeutics, 2019, 18, 1506-1519.	4.1	16
44	The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers, 2021, 13, 2621.	3.7	15
45	Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. PLoS Genetics, 2021, 17, e1009589.	3.5	15
46	Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies. Frontiers in Immunology, 2019, 10, 2990.	4.8	14
47	Mouse Models of Oncoimmunology in Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 5276-5286.	7.0	13
48	Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 317-325.	3.3	12
49	Iron overload and liver cancer. Journal of Experimental Medicine, 2019, 216, 723-724.	8.5	12
50	Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers. Frontiers in Immunology, 2021, 12, 642958.	4.8	12
51	Diverse immune response of DNA damage repair-deficient tumors. Cell Reports Medicine, 2021, 2, 100276.	6.5	12
52	The portrait of liver cancer is shaped by mitochondrial genetics. Cell Reports, 2022, 38, 110254.	6.4	10
53	Experimental Models for Preclinical Research in Hepatocellular Carcinoma. Molecular and Translational Medicine, 2019, , 333-358.	0.4	7
54	An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression. ELife, 2021, 10, .	6.0	7

#	ARTICLE	IF	CITATIONS
55	Strategies for HCC target discovery. Aging, 2017, 9, 1088-1089.	3.1	5
56	Functional screening to identify senescence regulators in cancer. Current Opinion in Genetics and Development, 2019, 54, 17-24.	3.3	5
57	Uncovering the role of USP54 in cancer. Oncotarget, 2017, 8, 10765-10766.	1.8	5
58	Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy. Journal of Hepatology, 2022, 77, 593-595.	3.7	5
59	The usual SASPects of liver cancer. Aging, 2015, 7, 348-349.	3.1	4
60	Hepatocellular carcinoma: killing one bird with two stones. Gut, 2019, 68, 1543-1544.	12.1	3
61	Turning up our understanding of liver cancer by a notch. Journal of Hepatology, 2021, 74, 502-504.	3.7	3
62	Manipulating and tracking single hepatocyte behavior during mouse liver regeneration by performing hydrodynamic tail vein injection. STAR Protocols, 2021, 2, 100440.	1.2	3
63	Proteomic Analyses Identify Therapeutic Targets in Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 814120.	2.8	3
64	Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease. Cancers, 2022, 14, 78.	3.7	3
65	To clear, or not to clear (senescent cells)? That is the question. Inside the Cell, 2016, 1, 87-95.	0.4	2
66	A Novel Long Noncoding RNA Finetunes the DNA Damage Response in Hepatocellular Carcinoma. Cancer Research, 2021, 81, 4899-4900.	0.9	2
67	Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 45-64.	0.1	1
68	Precision medicine in a dish. Science Translational Medicine, 2018, 10, .	12.4	1
69	Suppression of EZH2 Accelerates MYC-Driven Lymphomagenesis By Inhibition of Apoptosis. Blood, 2014, 124, 3009-3009.	1.4	1
70	A new hope for <i>KRAS</i> mutant cancers. Science Translational Medicine, 2018, 10, .	12.4	1
71	Imaging for better responses to immunotherapy in hepatocellular carcinoma. Hepatology, 2023, 77, 6-9.	7.3	1
72	CpG Island Hypermethylation, miRNAs, and Human Cancer. , 2008, , 367-384.		0

#	Article	IF	Citations
73	Metastasis Genes: Epigenetics. , 0, , 85-95.		0
74	Dissecting Early Relapse in Liver Cancer, One Cell at a Time. Hepatology, 2021, 74, 2891-2893.	7.3	0
75	Abstract 2935: RNAi screen identifies therapeutic targets in hepatocellular carcinoma. , 2014, , .		0
76	Abstract 2694: Histone acetyltransferase activity of MOF is required for MLL-AF9 leukemogenesis. , 2016, , .		0
77	Abstract 4393: Integrative molecular analysis of gene expression and methylation reveals 116 putative key regulator genes of human hepatocarcinogenesis. , 2017, , .		0
78	Abstract 1225: A unified model of RAF inhibitor action determines inhibitor activity in BRAF-dependent tumors. , 2017, , .		0
79	A (synthetic) lethal weapon for cancer. Science Translational Medicine, 2018, 10, .	12.4	0
80	Unsplicing senescence. Science Translational Medicine, 2018, 10, .	12.4	0
81	One hepatocyte, two malignant fates. Science Translational Medicine, 2018, 10, .	12.4	0
82	The two immune sides of obesity. Science Translational Medicine, 2018, 10, .	12.4	0
83	The more (mutations), the better. Science Translational Medicine, 2019, 11, .	12.4	0
84	Abstract LB-329: Pancancer proteomic investigation identifies overexpressed kinases as novel cancer dependent targets. , 2020, , .		0
85	Abstract NG06: CHD1-loss confers AR targeted therapy resistance via promoting cancer heterogeneity and lineage plasticity. , 2020, , .		0
86	Decoding therapy resistance in liver tumours: a giant leap. Nature Reviews Gastroenterology and Hepatology, 2021, , .	17.8	0
87	ÃŸ-catenin is a novel target in YAP-driven cholangiocarcinoma. Gastroenterology, 2022, , .	1.3	0